1 Result: Neuronetics
Biotech Companies Report Q1 Results: Neuronetics Beats Consensus, Voyager Therapeutics Surpasses Expectations, Y-mAbs Therapeutics Outperforms Estimates
May 09th, 2023
Neuronetics, Inc. (Nasdaq: STIM) has reported a Q1 loss of $0.38 per share, which was slightly better than the consensus loss of $0.39 per share. As of this writing, $STIM is trading at $2.89, up by 31.36% or $0.69. Meanwhile, Voyager Therapeutics. Read more
Want To Find Some News?
Recent Post
-
Honeywell, Intel, and Dover Earnings Preview: What to Expect
July 20th, 2025All Eyes on Tesla, ServiceNow, and GE Vernova Ahead of Earnings
July 20th, 2025RTX, Texas Instruments, and Northrop Grumman Earnings in Focus
July 20th, 2025
Member Login